



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_421_24

You asked:

Please see below a Freedom of Information request. Please answer the question with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

1. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period February 2024 to July 2024?
 - Azacitidine monotherapy
 - Low dose cytarabine (LoDAC) monotherapy
 - Venetoclax + azacitidine
 - Venetoclax + LoDAC
 - Ivosidenib
 - Intensive chemotherapy-based regimen
 - Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)
 - Best supportive care
 - Other
 - Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants

Note: this should only include patients with AML who have started first-line treatment during the 6-month window

Answer:

Treatment option	Number of newly diagnosed patients with AML starting first line treatment during the 6-month period February 2024 to July 2024
Azacitidine monotherapy	5
LoDAC monotherapy	0
Venetoclax + azacitidine	0
Venetoclax + LoDAC	0
Ivosidenib	0
Intensive chemotherapy-based regimen	0
Best supportive care	0
Other	0